| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cullinan Therapeutics Inc. | Zipalertinib (CLN-081/TAS6417) - (REZILIENT3) | Non-small cell lung Cancer (NSCLC) | Phase 3 | Ongoing | Oral | Oncology |
| Cullinan Therapeutics Inc. | Zipalertinib (CLN-081/TAS6417) - (REZILIENT1) | Non-small cell lung cancer | NDA Filing | Ongoing | Oral | Oncology |
| Cullinan Therapeutics Inc. | Zipalertinib - (REZILIENT2) | Locally advanced/metastatic NSCLC | Phase 2b | Data Released | Oral | Oncology |
| Cullinan Therapeutics Inc. | Zipalertinib - (REZILIENT2) | Locally advanced/metastatic NSCLC | Phase 2b | Data Released | Oral | Oncology |
| Cumberland Pharmaceuticals Inc. | Ifetroban | Aspirin-Exacerbated Respiratory Disease (AERD) | Phase 2 | Ongoing | Oral | Respiratory |
| Cumberland Pharmaceuticals Inc. | Ifetroban | Hepatorenal syndrome | Phase 2 | Trial Completed | Oral | Gastroenterology |
| Cumberland Pharmaceuticals Inc. | Ifetroban | Portal hypertension | Phase 2 | Trial Completed | Oral | Gastroenterology |
| Cumberland Pharmaceuticals Inc. | Ifetroban - (FIGHT DMD) | Cardiomyopathy associated with Duchenne Muscular Dystrophy | Phase 2 | Data Released | Oral | Genetic Disorder |